LIR-1 Educates Expanded Human NK Cells and Defines a Unique Antitumor NK Cell Subset with Potent Antibody-dependent Cellular Cytotoxicity
Overview
Authors
Affiliations
Objective: KIR and NKG2A receptors educate human NK cells to stay responsive to cells with diminished HLA class I. Here, we addressed whether the HLA class I-binding receptor LIR-1 (LILRB1/ILT2/CD85j), which is widely expressed on human NK cells, can mediate education and contribute to antitumor functions of NK cells.
Methods: Healthy donor NK cells either unstimulated, overnight cytokine-activated or -expanded were used to target human cell lines. Phenotype and function were analysed using flow cytometry and Cr-release assays.
Results: We found that the inhibitory receptor LIR-1 can mediate NK cell education under specific conditions. This novel finding was exclusive to expanded NK cells and further characterisation of the cells revealed high expression of granzyme B and DNAM-1, which both previously have been linked to NK cell education. Corroborating the rheostat education model, LIR-1 co-expression with an educating KIR further increased the responsiveness of expanded NK cells. Inversely, antibody masking of LIR-1 decreased the responsiveness. LIR-1 expanded NK cells displayed high intrinsic ADCC that, in contrast to KIR and NKG2A, was not inhibited by HLA class I.
Conclusion: These findings identify a unique NK cell subset attractive for adoptive cell therapy to treat cancer. Given that LIR-1 binds most HLA class I molecules, this subset may be explored in both autologous and allogeneic settings to innately reject HLA class I tumor cells as well as HLA class I target cells when combined with antitumor antibodies. Further studies are warranted to address the potential of this subset .
Maintaining the Balance: Regulation of NK Cell Activity.
Imsirovic V, Wensveen F, Polic B, Jelencic V Cells. 2024; 13(17.
PMID: 39273034 PMC: 11393908. DOI: 10.3390/cells13171464.
Natural killer cells and engagers: Powerful weapons against cancer.
Bottino C, Picant V, Vivier E, Castriconi R Immunol Rev. 2024; 328(1):412-421.
PMID: 39180430 PMC: 11659922. DOI: 10.1111/imr.13384.
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller T, Munnich I, Windisch R, Hilger P, Schewe D, Humpe A Front Immunol. 2023; 14:1240275.
PMID: 37781391 PMC: 10533923. DOI: 10.3389/fimmu.2023.1240275.
Wang H, Cui X, Zhang Y, Chen Y, Lu N, Bai L BMC Cancer. 2023; 23(1):486.
PMID: 37254046 PMC: 10228897. DOI: 10.1186/s12885-023-10823-4.
NK cell education: Physiological and pathological influences.
Rascle P, Woolley G, Jost S, Manickam C, Reeves R Front Immunol. 2023; 14:1087155.
PMID: 36742337 PMC: 9896005. DOI: 10.3389/fimmu.2023.1087155.